Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Shiloni

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Harefuah|February 15, 1995
[Kidney transplantation from living, related donors]O Gofrit, A Eid, M Friedlander, et al.
Harefuah|February 16, 1992
[CA15-3 tumor marker in early detection of breast cancer]I Roisman, E Shiloni, I Lifshiz, et al.
Cancer Treatment Reviews|June 1, 1989
Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II studyG Stoter, E Shiloni, S Gundersen, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II studyG Stoter, E Shiloni, S Aamdal, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II studyE Shiloni, P Pouillart, J Janssens, et al.
British Journal of Cancer|February 19, 2004
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanomaM Lotem, E Shiloni, I Pappo, et al.
Current Surgery|July 1, 1987
Staging of patients with suspected isolated colorectal liver metastasesA T Lefor, K S Hughes, E Shiloni, et al.
Diseases of the Colon and Rectum|February 1, 1988
Intra-abdominal extrahepatic disease in patients with colorectal hepatic metastasesA T Lefor, K S Hughes, E Shiloni, et al.
British Journal of Cancer|June 27, 2002
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on CancerM Lotem, T Peretz, O Drize, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1993
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factorS E Karp, A Farber, J C Salo, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Harefuah|February 15, 1995
[Kidney transplantation from living, related donors]O Gofrit, A Eid, M Friedlander, et al.
Harefuah|February 16, 1992
[CA15-3 tumor marker in early detection of breast cancer]I Roisman, E Shiloni, I Lifshiz, et al.
Cancer Treatment Reviews|June 1, 1989
Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II studyG Stoter, E Shiloni, S Gundersen, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II studyG Stoter, E Shiloni, S Aamdal, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II studyE Shiloni, P Pouillart, J Janssens, et al.
British Journal of Cancer|February 19, 2004
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanomaM Lotem, E Shiloni, I Pappo, et al.
Current Surgery|July 1, 1987
Staging of patients with suspected isolated colorectal liver metastasesA T Lefor, K S Hughes, E Shiloni, et al.
Diseases of the Colon and Rectum|February 1, 1988
Intra-abdominal extrahepatic disease in patients with colorectal hepatic metastasesA T Lefor, K S Hughes, E Shiloni, et al.
British Journal of Cancer|June 27, 2002
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on CancerM Lotem, T Peretz, O Drize, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1993
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factorS E Karp, A Farber, J C Salo, et al.
Pageof 9